Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 48 matches for

Evolvere joins our community for three months after winning the OUBT Biohacakthon 2021 BioEscalator sponsored prize.

A DNA strand with a lightbulb at the top. OUBT Biohackathon 2021 winner. Evolvere Bioscience logo.

Welcome, Sandbox Bioscience, to the BioEscalator Community!

We are excited to announce that Sandbox Bioscience, an ambitious biotech start-up founded by a team of virology experts from the Oxford ecosystem, has joined the BioEscalator.

Orfonyx Bio – big ambitions in protein upregulation

Orfonyx Bio is looking to make its mark as a leader in protein upregulation for clinical benefit – and has made technical progress towards this goal over the past two years. In that time as a BioEscalator tenant the University of Oxford spin-out has also grown from two to seven employees, raised an Oxford Science Enterprises-backed seed round and started to understand where its approach might have the greatest clinical impact. Now it’s raising additional funding.

The Gender Advantage: Building Inclusive and Thriving Ventures

To celebrate International Women's Day 2025, the BioEscalator was delighted to host a double panel discussion and networking event with EnSpire Oxford and Advanced Oxford.

BioEscalator Bulletin – Annual Review 2023/24 launched

The BioEscalator is delighted to have launched its inaugural Annual Review, ‘Driving innovation, advancing human health ’. It provides for the first time a discussion of our achievements in 2023/24, plus the milestones from our initial five years of operation.

Alethiomics – using Artemis to hunt down blood cancers

Spin-out company Alethiomics, focused on the development of innovative treatments for blood cancers, is Oxford through-and-through. Founded by Clinician Scientists who run neighbouring laboratories at the University’s MRC Weatherall Institute of Molecular Medicine, seed financed by Oxford Science Enterprises and located at the BioEscalator, the company’s early years have been immersed in the Oxford innovation ecosystem.

Leading academics and innovators join refreshed BioEscalator Management Board

In its first major refresh since its establishment in 2018, the BioEscalator is delighted to welcome five leading University of Oxford academics and innovators to its Management Board. Professors Catherine Green OBE, Beth Psaila, Molly Stevens DBE, Krina Zondervan and Peter Callow, Financial Controller of the Medical Sciences Division at the University of Oxford. The Management Board provides a source of expertise for BioEscalator tenants and works to enhance research at the University by building strong links with small life sciences companies.

A plant sciences spin-out flourishes at the BioEscalator

‘Mighty oaks from little acorns grow.’ And so it is with novel herbicide developer Moa Technology, which has grown from four people when it first became a BioEscalator tenant to a company of 85 with research facilities in Oxford and Yorkshire.

Eterna Biologics: Revolutionising RNA therapeutics

We are excited to welcome Eterna Biologics, a University of Oxford biotech spinout company with a mission to unleash the full potential of RNA medicines. The company aims to enhance global health by expanding the applicability of RNA-targeting medicine to develop treatment for a wide range of human conditions.

U-Ploid thrilled to join the BioEscalator Community

U-Ploid Biotechnologies joins the BioEscalator to develop groundbreaking therapeutics that improve egg quality and revolutionise IVF.

RE-AIM Therapeutics: Targeting disease causal cells to cure autoimmunity

We are delighted to welcome RE-AIM Therapeutics to the BioEscalator community, a start-up focused on developing antibody-based curative therapies for inflammatory disorders, such as psoriasis and inflammatory bowel disease.

The BioEscalator welcomes SiGenex to its growing community

SiGenex is advancing genomic medicine with its innovative, artificial intelligence-powered in-hospital sequencing platform. The company's technology is designed to transform how hospitals, clinics, and medical centres perform targeted next-generation sequencing (NGS) tests.

Bioarchitech graduates from the BioEscalator: A new chapter for innovative cancer therapy

Bioarchitech's departure from the BioEscalator marks the beginning of an exciting new phase for the pioneering cancer therapy company, as it transitions to the next stage of its innovative journey.

Highlights from the 5th annual BioEscalator Pitch Battle 2024

The 5th Annual BioEscalator Pitch Battle was an exciting showcase of fierce competition and groundbreaking innovations. With seven categories, ten companies competing for the top spot, and £2000 in prize money at stake, the judges faced a formidable task in selecting the winners.

Collaboration in action: Academic-industry stories

Our Business Manager, Dr Claire Shingler, participated in a collaborative project highlighting the strong partnerships between academic and industry professionals in the Medical Sciences Division. In this project, Claire shared her story and discussed her role in managing Oxford's biomedical science incubator. She discussed her motivations and the rewarding experiences she has had in supporting innovative spin-outs.

OSPT Ltd brings together ideas and experience for ‘astonishing’ success at the BioEscalator

The idea behind antibacterial company OSPT came to CEO and Founder Stephanie Lesage as she talked to haemodialysis patients as part of a research project, when it became clear to her that they had a really deep fear of the development of infection via their catheters. Their concerns were so significant that they almost outweighed the benefits of the dialysis treatment in the patients’ minds.

MediMabBio's graduation from the BioEscalator: A testament to innovation and growth

MediMab Biotherapeutics announces its graduation from the BioEscalator. This move represents a major milestone for the company as it relocates to Abingdon Science Park, positioning itself for further expansion and cutting-edge research in immuno-oncology.

Biohackathons, boot-strapping and Innovate UK backing – how Evolvere Biosciences is tackling antimicrobial resistance

A seminal study in The Lancet¹ estimates that in 2019 some 4.95 million deaths were associated with bacterial AMR, including 1.27 million deaths attributable to bacterial AMR. Evolvere is tackling this challenging unmet need using a platform combining synthetic biology, bioinformatics, and AI, designing new drugs plus generating AI models for other companies to license.

BiotechTV explores the BioEscalator's role in nurturing start-ups

Brad Loncar visited the BioEscalator to learn more about how we support the growth of innovative medical science companies.

MediMabBio - Two time zones, one mission

Two clocks are visible behind the Chief Scientific Officer of MediMabBio, Dr Chris Willberg, as he sits in the company office at the BioEscalator – showing time zones seven hours apart, they are a reminder of how teams in Seoul and Oxford are working together to discover new treatments for cancer and autoimmune disease.

It started with a brainstorm

Companies start in all kinds of different ways, and for Bioarchitech it was brainstorming that generated the idea behind the enterprise. It is now planning a Series A fundraising to bring its lead candidate to the clinic. Bioarchitech is focused on cancer, developing oncolytic viruses encoding protein immunotherapies for the destruction of tumours, ideally with just one or two doses.

Load More

Similar stories